Liver Diseases  >>  Asclevir (ravidasvir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
NCT01859962: Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark HepDART 2013
Dec 2013 - Dec 2013: HepDART 2013
Checkmark AASLD 2013
More
Completed
2a
38
US
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Presidio Pharmaceuticals, Inc., Boehringer Ingelheim
Chronic Hepatitis C
05/14
12/14

Download Options